Quintrio
Home

LABORATORY ANALYTICAL INSTRUMENTS

Seer, Inc. Class A Common Stock

SEER

Seer Inc is a life sciences company, develops and commercializes products to decode the biology of the proteome. The company offers Proteograph Product Suite, an integrated solution that includes proprietary engineered nanoparticles, consumables, automation instrumentation, and data analysis software to perform proteomic analysis to provide a solution that can be incorporated by nearly any lab for research use only. It markets and sells its products for research use only, which cover academic institutions, life sciences, and research laboratories, as well as biopharmaceutical and biotechnology companies for non-diagnostic and non-clinical purposes. The company operates in China, Australia, Eastern Europe, Israel, Japan and South Africa.

Last trade $1.44
Day change -$0.04 (-2.70%)
Day range $1.42 – $1.55
Volume 125,357
Market cap $83M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$82.61M
Price / earnings
—
Price / book
0.39×
Price / sales
5.87×
EV / sales
3.79×
EV / EBITDA
-0.88×

Profitability

Earnings per share
-$1.14
Return on assets
-26.25%
Return on equity
-29.81%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0×
Current ratio
16.89×
Quick ratio
16.24×
Cash ratio
2.95×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$46.35M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for SEER, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024
Revenue$3.98M$3.1M$2.79M$4.2M$4.12M$4.05M$4.21M$4M
Cost of revenue$2.1M$1.6M$1.81M$2.02M$2.01M$1.94M$2.14M$1.98M
Gross profit$1.88M$1.51M$982K$2.18M$2.11M$2.11M$2.06M$2.03M
Selling, general and administrative$10.11M$10.14M$9.43M$9.83M$10.66M$10.66M$11.44M$12.89M
Research and development$6.44M$8.21M$8.81M$9.74M$10.8M$11.99M$11.35M$12.62M
Total operating expenses$16.55M$18.35M$18.24M$19.57M$21.46M$22.64M$22.79M$25.51M
Operating income-$14.67M-$16.84M-$17.26M-$17.39M-$19.35M-$20.53M-$20.73M-$23.49M
Interest expense$0$0$0$0$0$0$0$0
Income before taxes-$13.73M-$16.89M-$16.83M-$15.97M-$18.21M-$19.38M-$19.85M-$21.64M
Income taxes$5K$9K$10K$28K$24K$48K$101K$98K
Net income-$13.74M-$16.9M-$16.84M-$15.99M-$18.23M-$19.42M-$19.95M-$21.74M
Net income attributable to common shareholders-$13.74M-$16.9M-$16.84M-$15.99M-$18.23M-$19.42M-$19.95M-$21.74M
EBITDA-$13.27M-$15.35M-$15.73M-$15.88M-$17.89M-$18.99M-$19.13M-$21.88M
Basic earnings per share-$0.25-$0.31-$0.30-$0.29-$0.32-$0.33-$0.34-$0.37
Diluted earnings per share-$0.25-$0.31-$0.30-$0.29-$0.32-$0.33-$0.34-$0.37

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
GlobeNewswire Inc.

Seer Stockholders Vote to Re-Elect All Seven of Seer’s Director Nominees at 2026 Annual Meeting

Seer, Inc. announced the re-election of all seven director nominees to its Board of Directors based on preliminary voting results from its 2026 Annual Meeting of Stockholders held on July 28, 2026. The company expressed confidence in its board's qualifications and commitment to advancing shareholder interests, while outlining its strategic focus on expanding platform utilization, securing biobank studies, advancing innovation, and scaling commercialization with cost discipline.

GlobeNewswire Inc.

Seer Files Investor Presentation Highlighting Strong Momentum, Commercial Opportunity and Significant Long-Term Value Creation Potential

Seer, Inc. filed an investor presentation ahead of its July 28, 2026 Annual Meeting, highlighting progress against strategic goals including 62% CAGR in installed base growth, 36% decrease in annual cash burn since 2022, and a robust innovation pipeline. The company's Board unanimously recommends voting for its seven director nominees and opposes activist investors Bradley Radoff and Michael Torok's campaign to force an early sale, arguing their proposals lack actionable value creation ideas and their nominees lack relevant proteomics expertise.

GlobeNewswire Inc.

Seer Confirms Receipt of Unsolicited Proposal and Director Candidate Nominations from Radoff-JEC Group

Seer, Inc. announced it has received an unsolicited acquisition proposal from Bradley L. Radoff and Michael Torok (Radoff-JEC Group) to acquire all outstanding Class A common stock for $2.25 per share in cash plus a contingent value right. The Radoff-JEC Group has also nominated three director candidates for the 2026 Annual Meeting. Seer's Board will carefully review the proposal and present its formal recommendation in the definitive proxy statement.

GlobeNewswire Inc.

Leading Scientists Demonstrate How Seer’s Proteograph Product Suite Advances Cardiovascular and Neurodegenerative Research at US HUPO 2026

Seer, Inc. announced its participation in the 2026 U.S. Human Proteome Organization (US HUPO) Annual Conference with over a dozen scientific presentations showcasing how its Proteograph Product Suite enables deep, scalable proteomics research across cardiovascular disease, neurodegeneration, aging biology, and oncology. The company will feature a breakfast symposium on nanoparticle-enabled plasma proteomics and multiple plenary and poster presentations demonstrating the technology's ability to detect thousands of proteins from small-volume samples.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.